Bright Minds Biosciences Inc. Collaborates with Firefly Neuroscience Inc. for EEG Data Analysis

Exciting Partnership for Neurological and Neuropsychiatric Disorders

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

This collaboration between Bright Minds Biosciences Inc. and Firefly Neuroscience Inc. marks a significant step forward in the field of neurology and neuropsychiatry. The use of AI technology in analyzing EEG data can provide valuable insights into the brain activity of patients with epilepsy and other neurological disorders, ultimately leading to better treatment options and improved outcomes.

Impact on Individuals

For individuals suffering from classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE), this collaboration offers hope for more effective therapies and personalized treatment plans. By utilizing advanced technology and innovative solutions, patients may experience improved quality of life and better management of their conditions.

Impact on the World

On a larger scale, the collaboration between Bright Minds Biosciences Inc. and Firefly Neuroscience Inc. has the potential to revolutionize the way neurological and neuropsychiatric disorders are diagnosed and treated. By combining the expertise of both companies, groundbreaking advancements in neuroscience and AI technology can be made, benefiting not only individual patients but society as a whole.

Conclusion

In conclusion, the collaboration between Bright Minds Biosciences Inc. and Firefly Neuroscience Inc. represents a significant milestone in the advancement of therapies for neurological and neuropsychiatric disorders. By leveraging AI technology to analyze EEG data, new insights can be gained that may lead to innovative treatment options and improved outcomes for patients around the world.